Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Shares in AstraZeneca PLC jumped 6 percent on Wednesday after the drug maker won a key patent battle in the United States over Seroquel, its anti-psychotic drug and second-best-seller.

The decision by a U.S. court to award a summary judgment in AstraZeneca’s favor avoids the need for a full trial and means that generic copies of the drug, which made $4 billion in sales last year, will not be launched in the near future.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.